{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T21:49:10Z","timestamp":1768081750602,"version":"3.49.0"},"reference-count":43,"publisher":"Croatian Society for Medical Biochemistry and Laboratory Medicine","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biochem. med. (Online)"],"published-print":{"date-parts":[[2021,6,15]]},"abstract":"<jats:p>Early detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and diagnosis of coronavirus disease 2019 (COVID-19) are priorities during the pandemic. Symptomatic and suspected asymptomatic individuals should be tested for COVID-19 to confirm infection and to be excluded from social interactions. As molecular testing capacity is overloaded during the pandemic, rapid antigen tests, such as lateral flow immunoassays (LFIAs), can be a useful tool as they allow greater test availability and obtain results in a very short time. This short review aims to present the analytical properties of LFIAs in the detection of SARS-CoV-2 in nasopharyngeal swabs. Lateral flow immunoassay is a method that combines thin-layer chromatography and indirect immunochemical sandwich method and allows the detection of a specific SARS-CoV-2 antigen in nasopharyngeal swabs. Swab specimens should be adequately collected and tested as soon as possible. Users should pay attention to quality control and possible interferences. Antigen tests for SARS-CoV-2 show high sensitivity and specificity in cases with high viral loads, and should be used up to five days after the onset of the first symptoms of COVID-19. False positive results may be obtained when screening large populations with a low prevalence of COVID-19 infection, while false negative results may happen due to improper specimen collection or insufficient amount of antigen in the specimen. So as to achieve reliable results, a diagnostic accuracy study of a specific rapid antigen test should be performed.<\/jats:p>","DOI":"10.11613\/bm.2021.020601","type":"journal-article","created":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T07:36:50Z","timestamp":1623310610000},"page":"230-239","source":"Crossref","is-referenced-by-count":17,"title":["Current status of the lateral flow immunoassay for the detection of SARS-CoV-2 in nasopharyngeal swabs"],"prefix":"10.11613","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8573-4294","authenticated-orcid":false,"given":"Anita","family":"Somborac Ba\u010dura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marija","family":"Doroti\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonarda","family":"Gro\u0161i\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"D\u017eimbeg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Slavica","family":"Dodig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4885","published-online":{"date-parts":[[2021,6,15]]},"reference":[{"key":"key20210610033526_r1","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","article-title":"Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding.","volume":"395","author":"Lu","year":"2020","journal-title":"Lancet"},{"key":"key20210610033526_r2","doi-asserted-by":"crossref","first-page":"m606","DOI":"10.1136\/bmj.m606","article-title":"Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series.","volume":"368","author":"Xu","year":"2020","journal-title":"BMJ"},{"key":"key20210610033526_r3","article-title":"Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19 disease.","volume":"7","author":"Struyf","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"key20210610033526_r4","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1053\/j.gastro.2020.04.017","article-title":"Gastrointestinal symptoms and coronavirus disease 2019: A case-control study from the United States.","volume":"159","author":"Nobel","year":"2020","journal-title":"Gastroenterology"},{"key":"key20210610033526_r5","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41569-020-0413-9","article-title":"COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives.","volume":"17","author":"Nishiga","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"key20210610033526_r6","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.15585\/mmwr.mm6936a5","article-title":"CDC COVID-19 Response Team. Community and close contact exposures associated with COVID-19 among symptomatic adults \u226518 years in 11 outpatient health care facilities - United States, July 2020.","volume":"69","author":"Fisher","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key20210610033526_r7","unstructured":"Appendix A - Glossary of key terms. Centers for Disease Control and Prevention. Available at: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/php\/contact-tracing\/contact-tracing-plan\/appendix.html. Accessed December 16th 2020."},{"key":"key20210610033526_r8","doi-asserted-by":"crossref","first-page":"577","DOI":"10.7326\/M20-0504","article-title":"The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application.","volume":"172","author":"Lauer","year":"2020","journal-title":"Ann Intern Med"},{"key":"key20210610033526_r9","unstructured":"Interim guidance for antigen testing for SARS-CoV-2. Centers for Disease Control and Prevention. Available at: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/lab\/resources\/antigen-tests-guidelines.html. Accessed December 16th 2020."},{"key":"key20210610033526_r10","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1002\/jmv.26326","article-title":"Proportion of asymptomatic coronavirus disease 2019: A systematic review and meta-analysis.","volume":"93","author":"He","year":"2021","journal-title":"J Med Virol"},{"key":"key20210610033526_r11","doi-asserted-by":"crossref","DOI":"10.11613\/BM.2020.030901","article-title":"Comparison of a rapid immunochromatographic test with a chemiluminescence immunoassay for detection of anti-SARS-CoV-2 IgM and IgG.","volume":"30","author":"Gambino","year":"2020","journal-title":"Biochem Med (Zagreb)"},{"key":"key20210610033526_r12","unstructured":"Diagnostic testing for SARS-CoV-2 (Interim guidance, 11 September 2020). World Health Organization. Available at: https:\/\/www.who.int\/publications\/i\/item\/diagnostic-testing-for-sars-cov-2. Accessed March 12th 2021."},{"key":"key20210610033526_r13","doi-asserted-by":"crossref","first-page":"905","DOI":"10.3390\/diagnostics10110905","article-title":"Development of diagnostic test for detection of SARS-CoV-2.","volume":"10","author":"Nguyen","year":"2020","journal-title":"Diagnostics (Basel)"},{"key":"key20210610033526_r14","unstructured":"Coronavirus (COVID-19) update: FDA issues first Emergency Use Authorization for point of care diagnostic. US Food and Drug Administration. Available at: https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-issues-first-emergency-use-authorization-point-care-diagnostic. Accessed December 10th 2020."},{"key":"key20210610033526_r15","unstructured":"COVID-19 in vitro diagnostic devices and test methods database. European Commission. Available at: https:\/\/covid-19-diagnostics.jrc.ec.europa.eu\/devices?marking=&principle=ImmunoAssay-Antigen&format=&manufacturer=&text_name=&orderBy=Manufacturer&invertedOrder=#form_content. Accessed December 10th 2020."},{"key":"key20210610033526_r16","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1042\/EBC20150012","article-title":"Lateral flow assays.","volume":"60","author":"Koczula","year":"2016","journal-title":"Essays Biochem"},{"key":"key20210610033526_r17","unstructured":"Considerations for Use of SARS-CoV-2 Antigen Testing in Nursing Homes. Centers for Disease Control and Prevention. Available at: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/hcp\/nursing-homes-antigen-testing.html. Accessed December 10th 2020."},{"key":"key20210610033526_r18","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1515\/cclm-2020-1413","article-title":"IFCC Interim Guidelines on Serological Testing of Antibodies against SARS-CoV-2.","volume":"58","author":"Bohn","year":"2020","journal-title":"Clin Chem Lab Med"},{"key":"key20210610033526_r19","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.3390\/v12121420","article-title":"Comparison of rapid antigen tests for COVID-19.","volume":"12","author":"Yamayoshi","year":"2020","journal-title":"Viruses"},{"key":"key20210610033526_r20","unstructured":"Use of rapid antigen tests. Reference Center for Epidemiology of the Ministry of Health; Croatian Institute of Public Health. Available at: https:\/\/www.koronavirus.hr\/UserDocsImages\/Dokumenti\/Upotreba_brzih_antigenskih_testova_26_11.pdf. Accessed December 10th 2020. (in Croatian)"},{"key":"key20210610033526_r21","unstructured":"Nasopharyngeal (NP) specimen collection steps. Centers for Disease Control and Prevention. Available at: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/downloads\/lab\/NP_Specimen_Collection_Infographic_FINAL_508.pdf. Accessed December 14th 2020."},{"key":"key20210610033526_r22","unstructured":"Interim guidelines for collecting, handling, and testing clinical specimens for COVID-19. Centers for Disease Control and Prevention. Available at: https:\/\/www.cdc.gov\/coronavirus\/2019-nCoV\/lab\/guidelines-clinical-specimens.html. Accessed December 14th 2020."},{"key":"key20210610033526_r23","doi-asserted-by":"crossref","unstructured":"Frequently asked questions about coronavirus (COVID-19) for laboratories: Accessing laboratory testing. Centers for Disease Control and Prevention. Available at: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/lab\/faqs.html#Accessing-Laboratory-Testing. Accessed December 14th 2020. https:\/\/doi.org\/10.24321\/2455.7048.202004","DOI":"10.24321\/2455.7048.202004"},{"key":"key20210610033526_r24","unstructured":"Viral transport media (VTM) - principle, preparation, uses, limitations. Microbe Notes. Available at: https:\/\/microbenotes.com\/viral-transport-media-vtm\/#viral-transport-media-vtm-definition. Accessed December 15th 2020."},{"key":"key20210610033526_r25","doi-asserted-by":"crossref","first-page":"e00590","DOI":"10.1128\/JCM.00590-20","article-title":"Evaluation of saline, phosphate-buffered saline, and minimum essential medium as potential alternatives to viral transport media for SARS-CoV-2 testing.","volume":"58","author":"Rodino","year":"2020","journal-title":"J Clin Microbiol"},{"key":"key20210610033526_r26","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.jmoldx.2020.04.209","article-title":"Detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is comparable in clinical samples preserved in saliva or viral transport medium.","volume":"22","author":"Radbel","year":"2020","journal-title":"J Mol Diagn"},{"key":"key20210610033526_r27","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.3390\/v12111208","article-title":"Evaluation of commercially available viral transport medium (VTM) for SARS-CoV-2 inactivation and use in point-of-care (POC) testing.","volume":"12","author":"van Bockel","year":"2020","journal-title":"Viruses"},{"key":"key20210610033526_r28","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1128\/JCM.02047-07","article-title":"Comparison of the Copan ESwab system with two Amies agar swab transport systems for maintenance of microorganism viability.","volume":"46","author":"Van Horn","year":"2008","journal-title":"J Clin Microbiol"},{"key":"key20210610033526_r29","doi-asserted-by":"crossref","unstructured":"Guidelines for submitting specimens to CDC for laboratory testing for SARS-CoV-2. Centers for Disease Control and Prevention. Available at: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/downloads\/COVID-19-Specimen-Submission-Guidance.pdf. Accessed December 15th 2020. https:\/\/doi.org\/10.46234\/ccdcw2020.085","DOI":"10.46234\/ccdcw2020.085"},{"key":"key20210610033526_r30"},{"key":"key20210610033526_r31","doi-asserted-by":"crossref","first-page":"11305","DOI":"10.1021\/acs.analchem.0c01975","article-title":"SARS-CoV-2 coronavirus nucleocapsid antigen-detecting half-strip lateral flow assay toward the development of point of care tests using commercially available reagents.","volume":"92","author":"Grant","year":"2020","journal-title":"Anal Chem"},{"key":"key20210610033526_r32","unstructured":"CareStartTM COVID-19 Antigen. Rapid diagnostic test for the detection of SARS-CoV-2 antigen. US Food and Drug Administration. Available at: https:\/\/www.fda.gov\/media\/142919\/download. Accessed December 17th 2020."},{"key":"key20210610033526_r33"},{"key":"key20210610033526_r34","doi-asserted-by":"crossref","first-page":"50","DOI":"10.11613\/BM.2009.005","article-title":"Interferences in quantitative immunochemical methods.","volume":"19","author":"Dodig","year":"2009","journal-title":"Biochem Med (Zagreb)"},{"key":"key20210610033526_r35","unstructured":"Binax NOWTM. COVID-19 Ag CARD (Abbott, PN 195-000) \u2013 Instructions for use. US Food and Drug Administration. Available at: https:\/\/www.fda.gov\/media\/141570\/download?fbclid=IwAR1rxA9e3V3pH7O-m17ctmvdVyk-D1sh-U80rTODfrqoWu-QRLkcv2qXIAo. Accessed December 17th 2020."},{"key":"key20210610033526_r36","unstructured":"CDC indicators and thresholds for risk of introduction and transmission of COVID-19 in schools. Centers for Disease Control and Prevention. Available at: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/community\/schools-childcare\/indicators.html#thresholds. Accessed December 15th 2020."},{"key":"key20210610033526_r37","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcv.2020.104455","article-title":"Low performance of rapid antigen detection test as frontline testing for COVID-19 diagnosis.","volume":"129","author":"Scohy","year":"2020","journal-title":"J Clin Virol"},{"key":"key20210610033526_r38","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1515\/dx-2020-0131","article-title":"Making sense of rapid antigen testing in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) diagnostics.","volume":"8","author":"Mattiuzzi","year":"2020","journal-title":"Diagnosis (Berl)"},{"key":"key20210610033526_r39","article-title":"Clinical assessment of the Roche SARS-CoV-2 rapid antigen test.","volume":"\u2022\u2022\u2022","author":"Salvagno","year":"2021","journal-title":"Diagnosis (Berl)"},{"key":"key20210610033526_r40","unstructured":"Why Pretest and Posttest Probability Matter in the Time of COVID-19. American Society for Microbiology. Available at: https:\/\/asm.org\/Articles\/2020\/June\/Why-Pretest-and-Posttest-Probability-Matter-in-the. Accessed December 15th 2020."},{"key":"key20210610033526_r41","unstructured":"Options for the use of rapid antigen tests for COVID-19 in the EU\/EEA and the UK. European Centre for Disease Prevention and Control. Available at: https:\/\/www.ecdc.europa.eu\/sites\/default\/files\/documents\/Options-use-of-rapid-antigen-tests-for-COVID-19.pdf. Accessed December 15th 2020."},{"key":"key20210610033526_r42","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.ijid.2020.05.098","article-title":"Evaluation of a novel antigen-based rapid detection test for the diagnosis of SARS-CoV-2 in respiratory samples.","volume":"99","author":"Porte","year":"2020","journal-title":"Int J Infect Dis"},{"key":"key20210610033526_r43","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2020.11.004","article-title":"Field evaluation of a rapid antigen test (Panbio COVID-19 Ag Rapid Test Device) for COVID-19 diagnosis in primary healthcare centres.","volume":"27","author":"Albert","year":"2021","journal-title":"Clin Microbiol Infect"}],"container-title":["Biochemia medica"],"original-title":[],"link":[{"URL":"https:\/\/www.biochemia-medica.com\/en\/journal\/31\/2\/10.11613\/BM.2021.020601\/fullArticle","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,19]],"date-time":"2021-07-19T15:20:46Z","timestamp":1626708046000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.biochemia-medica.com\/en\/journal\/31\/2\/10.11613\/BM.2021.020601"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,15]]},"references-count":43,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,6,15]]},"published-print":{"date-parts":[[2021,6,15]]}},"URL":"https:\/\/doi.org\/10.11613\/bm.2021.020601","relation":{},"ISSN":["1846-7482","1330-0962"],"issn-type":[{"value":"1846-7482","type":"electronic"},{"value":"1330-0962","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6,15]]}}}